🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

New #JITC article: Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors bit.ly/3ujIkao Markus Joerger @ElenaGarralda Heinz Läubli

Tetra- and Hexavalent Siglec-8 Ligands Modulate Immune Cell Activation (Beat Ernst and co-workers) Heinz Läubli Universität Basel Department of Biomedicine onlinelibrary.wiley.com/doi/10.1002/an…

EPFL DKFZ Immunology Infection and Cancer Université de Genève @FondationIsrec Link: nature.com/articles/s4301…

Interesting finding by Michela Manni and colleagues. Neu5Gc-containing lipids in the skin. #glycotime Detection of N-glycolyl-neuraminic acid-containing glycolipids in human skin frontiersin.org/articles/10.33…

David König presenting data from our BaseTIL trial combining tumor-infiltrating lymphocyte therapy with nivolumab at the #ESMOImmuno23

Nice overview on my former mentor, Ajit Varki's work on the role of sialic acid in host-pathogen interactions and evolution #glycotime Sickly sweet: how our sugar-coated cells helped humanity turn illness into evolution theguardian.com/science/2023/d…

OPEN POSITION💡 The Cancer Immunotherapy group led by Heinz Läubli Heinz Läubli is looking for a highly collaborative research associate with a goal-oriented mindset. Link Job offer: jobs.unibas.ch/offene-stellen…

Nice work by Flavio Schwarz and his team at InterVenn Biosciences showing that PD-1 blocking antibodies depend on PD-1 glycosylation. #glycotime Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors life-science-alliance.org/content/7/3/e2…

New #JITC position article and guidelines: Corticosteroid-resistant immune-related adverse events: a systematic review bit.ly/3u0egRp Heinz Läubli Alfred Zippelius @cappelliMD Jarushka Naidoo

Pioneering chemist and Nobel Laureate Carolyn R. Bertozzi, PhD, FAACR, is excited about the new frontier of cancer therapies powered by chemistry. Learn how she is making an impact in this AACR Stories piece: bit.ly/3OKnqsw Carolyn Bertozzi Sarafan ChEM-H #AACRFellows

Great to see our paper published today in communications biology which reports ST3Gal1 to synthesise Siglec-7 and Siglec-9 ligands critical to maintaining immune suppression within the prostate TIME Emma Scott🥳 nature.com/articles/s4200…

Great work by Ronja Wieboldt and Natalia Mantuano in our lab Department of Biomedicine . They show that myeloid-derived suppressors are inhibiting efficient anti-tumor immunity by secreting CCL2 induced by sialic acid-Siglec interactions. #glycotime rdcu.be/dAt5I

🚨Review on TIM-3!🚨 science.org/doi/10.1126/sc… We all know TIM-3 is an important checkpoint molecule on T cells! *But* here we (Gonzalo & Kuchroo Lab) review emerging evidence demonstrating unexpected roles for TIM-3 as a key regulator of myeloid cell function.

This year’s Otto Naegeli Prize for Medical Research goes to Professor Mirjam Christ-Crain 🇪🇺🇨🇭. The award, which is endowed with CHF 200,000, is considered one of Switzerland’s most important scientific prizes. unibas.ch/en/News-Events…

Nature research paper: Selective haematological cancer eradication with preserved haematopoiesis go.nature.com/4aBDWmC

Like a mixing console blending not songs but blood systems: Researchers demonstrate how to specifically shut down a #leukemia-affected blood system and simultaneously build a new one. Department of Biomedicine UniSpitalBaselCH unibas.ch/en/News-Events…

Our first TIL trial UniSpitalBaselCH and University of Basel combining TIL therapy with PD-1 blocking nivolumab in patients with metastatic melanoma. esmoiotech.org/article/S2590-…

New manuscript by Andreas Zingg and colleagues describing the development of STn-specific CAR T cells. Targeting cancer-associated glycosylation for adoptive T cell therapy of gastro-intestinal and gynecological cancers biorxiv.org/content/10.110…

Happy to share our latest Review article discussing current challenges in Tumour Glyco-Immunology, together with ⁦Heinz Läubli⁩ and Matthew Macauley! #glycotime ⁦Journal for ImmunoTherapy of Cancer⁩ ⁦i3S-Instituto de Investigação e Inovação em Saúde⁩ jitc.bmj.com/content/13/6/e…